(103 days)
No
The device description focuses on the mechanical properties and design of the implants and instrument system, with no mention of AI or ML technology.
Yes
The device is intended for sacroiliac fusion to treat various sacroiliac joint conditions, which is a therapeutic purpose.
No
The provided text describes the iFuse Implant System as an implant system used for sacroiliac fusion to stabilize the sacroiliac joint or fracture. Its function is to prevent and minimize motion/micromotion and facilitate fusion, which are therapeutic actions, not diagnostic ones.
No
The device description explicitly states it consists of titanium implants and an instrument system, which are hardware components.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
- Device Description: The iFuse Implant System is a surgical implant designed to stabilize and fuse the sacroiliac joint. It is a physical device implanted into the body.
- Intended Use: The intended use is for sacroiliac fusion to treat specific conditions of the sacroiliac joint. This is a surgical intervention, not a diagnostic test performed on a specimen.
The description clearly indicates a device used in vivo (within the body) for treatment, not in vitro (in a lab) for diagnosis.
N/A
Intended Use / Indications for Use
The iFuse Implant System is intended for sacroiliac fusion for the following conditions:
· Sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the period and have persisted postpartum for more than 6 months.
· To augment immobilization and stabilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion.
· Acute, non-acute, and non-traumatic fractures involving the sacroiliac joint.
Product codes (comma separated list FDA assigned to the subject device)
OUR
Device Description
The iFuse Implant System consists of cannulated triangular, titanium implants Ti-6A1-4V ELI, ASTM F136/F1580 and iFuse-3D implants: Ti-6A1-4V ELI, ASTM F3001 with a porous surface and an instrument system. The principle of operation is based on the triangular implant shape and porous surface which are designed to prevent and minimize motion / micromotion of the sacroiliac (SI) joint, and thereby stabilize the joint or fracture. The mechanism of action is that the interference fit allows for fixation, stabilization and fusion. The implants are available in varying lengths and diameters and are provided sterile (gamma sterilization).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
sacroiliac joint
Indicated Patient Age Range
skeletally mature patients
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
There were no changes in the design, technological features, intended use and overall risks associated with the iFuse Implant System. Therefore, no new design verification or validation testing was required; the design verification and validation testing previously conducted and submitted in previously cleared SI-BONE 510(k)s is applicable.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 888.3040 Smooth or threaded metallic bone fixation fastener.
(a)
Identification. A smooth or threaded metallic bone fixation fastener is a device intended to be implanted that consists of a stiff wire segment or rod made of alloys, such as cobalt-chromium-molybdenum and stainless steel, and that may be smooth on the outside, fully or partially threaded, straight or U-shaped; and may be either blunt pointed, sharp pointed, or have a formed, slotted head on the end. It may be used for fixation of bone fractures, for bone reconstructions, as a guide pin for insertion of other implants, or it may be implanted through the skin so that a pulling force (traction) may be applied to the skeletal system.(b)
Classification. Class II.
0
March 31, 2020
Image /page/0/Picture/1 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
Si-Bone, Inc Susan Noriega Sr. Director Regulatory Affairs 47 El Camino Real, Suite 101 Santa Clara, California 95050
Re: K193524
Trade/Device Name: SI-BONE iFuse Implant System® Regulation Number: 21 CFR 888.3040 Regulation Name: Smooth Or Threaded Metallic Bone Fixation Fastener Regulatory Class: Class II Product Code: OUR Dated: March 4, 2020 Received: March 5, 2020
Dear Susan Noriega:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see
1
https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
for
Colin O'Neill, MBE Assistant Director (Acting) DHT6B: Division of Spinal Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K193524
Device Name SI-BONE iFuse Implant System®
Indications for Use (Describe)
The iFuse Implant System is intended for sacroiliac fusion for the following conditions:
· Sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the period and have persisted postpartum for more than 6 months.
· To augment immobilization and stabilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion.
· Acute, non-acute, and non-traumatic fractures involving the sacroiliac joint.
| Type of Use (Select one or both, as applicable) |
|---|
| ------------------------------------------------- |
|X | Prescription Use (Part 21 CFR 801 Subpart D)
_ Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/1 description: The image shows the logo for SI-BONE's iFuse Implant System. The logo features the company name "SI-BONE" in bold, black letters, with a green graphic element integrated into the "BONE" portion. To the right of the company name, the text "iFuse Implant System" is displayed in a larger, bold font. Below this, the phrase "Minimally Invasive Sacroiliac Joint Surgery" is written in a smaller font, providing additional context about the system's purpose.
510(k) SUMMARY
SI-BONE iFuse Implant System®
DATE PREPARED I.
March 4, 2020
II. 510(k) SUBMITTER
SI-BONE, Inc. 471 El Camino Real, Suite 101, Santa Clara, CA 95050 Phone: 408-207-0700 Fax: 408-557-8312
Contact Person: Susan Noriega, Sr. Director Regulatory Affairs
FDA Establishment Registration No .: 3007700286
III. DEVICE
| Trade Name of Device: | SI-BONE iFuse Implant System® |
|---|---|
| Common or Usual Name: | Sacroiliac Joint Fixation |
| Classification: | II |
| Regulation Number: | 21 CFR 888.3040, Smooth or threaded metallic bone fastene |
| Product Code: | OUR |
PREDICATE DEVICE IV.
| SI-BONE iFuse Implant System® | K190230 (Primary Predicate) |
|---|---|
| SI-BONE iFuse Implant System® | K110838, K092375, K080298 (Reference Predicates) |
V. DEVICE DESCRIPTION
The iFuse Implant System consists of cannulated triangular, titanium implants Ti-6A1-4V ELI, ASTM F136/F1580 and iFuse-3D implants: Ti-6A1-4V ELI, ASTM F3001 | with a porous surface and an instrument system. The principle of operation is based on the triangular implant shape and porous surface which are designed to prevent and minimize motion / micromotion of the sacroiliac (SI) joint, and thereby stabilize the joint or fracture. The mechanism of action is that the interference fit allows for fixation, stabilization and fusion. The implants are available in varying lengths and diameters and are provided sterile (gamma sterilization).
4
VI. INDICATIONS FOR USE
The iFuse Implant System is intended for sacroiliac fusion for the following conditions:
- Sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative . sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months.
- To augment immobilization and stabilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion.
- Acute, non-acute, and non-traumatic fractures involving the sacroiliac joint. ●
VII. SUMMARY OF SUBSTANTIAL EQUIVALENCE
There are no changes to the technological characteristics of the device that are the subject of this 510(k). SI-BONE's iFuse Implant System is technologically identical to and has the same intended use and substantially similar indications for use as the previously cleared predicate devices (K190230; as well as the reference predicates cleared in K110838, K080398 and K092375). The proposed indications for use statement does not introduce any new indications, does not alter the therapeutic effect or use of the implants and does not expand use of the implants beyond uses contemplated under the cleared predicate 510(k)s. In conclusion, the iFuse Implant System with clarified indication for use statement is substantially equivalent to the predicate devices.
VIII. SUMMARY OF VERIFICATION AND VALIDATION ACTIVITIES
There were no changes in the design, technological features, intended use and overall risks associated with the iFuse Implant System. Therefore, no new design verification or validation testing was required; the design verification and validation testing previously conducted and submitted in previously cleared SI-BONE 510(k)s is applicable.
SI-BONE follows established quality system and design control requirements in accordance with the Quality System Regulation (21 CFR 820) and declares conformance to design controls and risk-based assessment procedures, including Hazards Analysis and Use FMEA assessments.
CONCLUSION IX.
The intended use and the technological characteristics are unchanged compared to the predicate device, therefore the subject device is substantially equivalent to the predicate device.